Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | STK11 inact mut |
| Therapy | Everolimus |
| Indication/Tumor Type | lung adenocarcinoma |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| STK11 inact mut | lung adenocarcinoma | predicted - sensitive | Everolimus | Case Reports/Case Series | Actionable | In a Phase II trial, Afinitor (everolimus) treatment resulted in a complete response lasting more than 10 months in a heavily pre-treated patient with lung adenocarcinoma harboring 2 in cis non-coding STK11 mutations (STK11 c.375-2del and c.375-G>C), (PMID: 34422335; NCT02352844). | 34422335 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (34422335) | A phase II study of everolimus in patients with advanced solid malignancies with TSC1, TSC2, NF1, NF2 or STK11 mutations. | Full reference... |